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Original Article 
Serological assessment of measles–rubella vaccination catch-up 
campaign among university students 
Jiro Takeuchi,1 Masashi Goto,1 Takashi Kawamura1 and Atsushi Hiraide2  
1Health Service, Kyoto University, Kyoto and 2Department of Acute Medicine, Kinki University Faculty of Medicine, Osaka-
Sayama, Japan 
Abstract 
Background: In Japan, 5000–300 000 persons succumbed to measles every year until 2001. The 
measles/rubella-combined (MR) vaccination at age 17–18 years (phase 4 MR vaccination: MR-IV) was launched in 
2008 in Japan as a measles–rubella catch-up campaign. A serological assessment of this campaign has not been 
thoroughly performed. 
Methods: Titers of anti-measles and anti-rubella immunoglobulin G antibodies, and past medical history including 
measles and rubella vaccination and infection were obtained from first-year university students in 2008 and 2009, and 
the immune status against measles and rubella was compared between students at the target MR-IV age (the target 
age group) and those 1 year older than the target age (non-target age group). 
Results: A total of 186 students were in the target age group and 146 were in the non-target age group. The 
proportion of students with a history of measles and rubella infection was not significantly different between the two 
groups (8.8% vs. 6.3%, P = 0.41 and 11.0% vs. 9.9%, P = 0.75, respectively). A history of two or more measles and 
rubella vaccinations was significantly more frequent in the target age group (85.2% and 54.9%, respectively) than in 
the non-target age group (20.8% and 13.2%, respectively; both P < 0.001). Prevalence of seropositivity for measles 
and for rubella was also higher in the target age group (98.9% and 97.8%, respectively) than in the non-target age 
group (91.0% and 87.5%, respectively; both P < 0.001). 
Conclusions: The MR-IV catch-up campaign helped achieve herd immunity and will contribute to the 
elimination of measles and rubella. 
Key words antibody, catch-up campaign, maternal and child health handbook, measles–rubella vaccination, 
university students. 
In the past the government of Japan mandated people to receive only a single-dose 
vaccination for measles and rubella, and partially due to this 5000–300 000 persons had 
succumbed to measles every year before 2001.1,2 Mathematical models indicated that 
>95% of people in a community should be immunized to prevent an epidemic of 
measles, and the corresponding proportion is 85% for rubella.3–5 The World Health 
Organization (WHO), therefore, recommends 95% immunization to eliminate measles,6 
but only 80.7% of Japanese people of all ages had received immunization for measles in 
2001.7 The government then launched a campaign with the theme “Give a measles 
vaccine as a first birthday gift!” in 2001.8 
Nevertheless, Japan experienced measles outbreaks mainly among high school and 
college students in both 2006 and 2007. Especially in 2007, 1657 students (0.58%) 
suffered from measles nationwide.9 Prevention of vaccine-preventable infectious 
diseases among youth then became an urgent matter. The greatest concerns were non-
vaccination and vaccine failure. Indeed, a survey during the measles outbreak found that 
only 64.8% of patients had a history of measles vaccination.10 Vaccine failure occurred 






Therefore, a two-dose policy with a measles/rubella-combined (MR) vaccine, requiring 
immunization at age 12–23 months (phase 1 MR vaccination: MR-I) and at age 5–
6 years (just before school entry, phase 2 MR vaccination: MR-II) was enforced in 2006, 
not only to increase vaccine coverage but also to minimize vaccine failure.12–16 In 
addition, a catch-up campaign with MR vaccinations at age 12–13 years (first-year 
junior high school students, phase 3 MR vaccination: MR-III) and at age 17–18 years 
(third-year high school students, phase 4 MR vaccination: MR-IV), has been carried out 
for 5 years since 2008 under the Preventive Vaccination Law.6 
By these efforts, the annual number of measles cases decreased from an estimated 
286 000 in 2001 to 11 005 in 2008, 741 in 2009, 457 in 2010, and 434 in 2011.7,17–20 
The number of measles outbreaks also rapidly decreased after peaking in 2007, and 
there has been no remarkable outbreak from 2009 on. According to the pediatric fixed-
point survey of measles, the proportion of patients aged ≥10 years gradually increased, 
while that of patients aged 1–4 years gradually decreased until 2007.21 The proportion 
of patients ≥10 years old, however, has dramatically decreased since 2008 when the 
catch-up campaign was introduced. The catch-up campaign seems successful in 
preventing measles and rubella epidemics among adolescents. The two-dose vaccination 
campaign has been known to reduce the incidence of measles early in the following year, 
as it did in England and Wales. We, therefore sought to evaluate the efficacy of the 
catch-up campaign in detail.22 
Methods 
Study design 
This study was carried out as an analytical epidemiological study at a single institution. 
The 2008 and 2009 first-year students of Kyoto University Faculty of Medicine (School 
of Medicine, medical doctor course, and School of Human Health Sciences, co-medical 
professional course) and Faculty of Pharmaceutical Sciences (Division of Pharmacy, 
pharmacist course) were invited to participate in the study. Because the MR-IV 
launched in 2008 for 5 years was targeted at last year (third-year) high school students, 
first-year students in 2009 who entered the university right after graduating from high 
school were at the target MR-IV age. Meanwhile, all of the first-year students in 2008 
were off the target MR-IV age. We therefore recruited the students who entered the 
university right after graduating from high school, both in 2009 and 2008, for the study. 
Individual written informed consent was obtained from all participants. After merging 
data from different sources, all personal identifiers were removed from the database. 
This investigation was approved by the Ethics Committee of Kyoto University Graduate 
School of Medicine (approval number, E-590). 
Questionnaire survey 
An informed consent form and a self-administered questionnaire with a reply envelope 
were handed out to the 2009 first-year students and mailed to the 2008 first-year 
students. The questionnaire included items on demographic characteristics and past 
medical history, including measles and rubella infection. Students were asked to 
complete the questionnaire and return it with the consent form and a photocopy of the 
immunization record from the Maternal and Child Health (MCH) Handbook. 
Unfortunately, however, the welfare committee of the School of Human Health 
Sciences did not allow us to collect photocopies of the MCH Handbook for the 2008 
first-year co-medical students due to a lack of time for obtaining their consent. 
The MCH Handbook is issued by the local government of one’s residential area, and 
entries are completed by medical professionals mainly at pre- and postnatal periodic 







Titers of anti-measles and anti-rubella immunoglobulin (Ig) G antibodies were 
measured on enzyme immunoassay (EIA) and hemagglutination inhibition (HI) test, on 
23, 24 and 27 June 2008, or 2 April 2009, respectively. Microbiology tests were 
examined by a clinical laboratory company outside Kyoto University, Kyoto Medical 
Science Laboratory. The cut-off levels of anti-measles and anti-rubella antibody titers 
were set at 6.0 IU/mL and 8 (dilution ratio of 1:8), respectively.23 An HI titer 8–10 
corresponds to an EIA level of 15 IU/mL.24 During the research period, no incidence of 
measles or rubella was reported on campus. 
Statistical analysis 
Vaccine coverage, antibody titer levels and the prevalences of seropositivity for measles 
and rubella were compared between the two groups: the target age group and the non-
target age group. The antivirus antibody titers were logarithmically transformed to be 
normalized for statistical tests. For comparison, Student’s t-test was used for continuous 
variables after confirmation of normality, and Pearson’s chi-squared test or Fisher’s 
exact test was used for categorical variables. All tests of significance were two-tailed, 
and P < 0.05 was considered statistically significant. Statistical analysis was done with 
STATA 10.0 (STATA, College Station, TX, USA). 
Results 
Student characteristics 
A total of 379 eligible students (129 medical, 202 co-medical, and 48 pharmaceutical), 
were invited to participate, and 332 who consented (87.6% in total; 91.6% in the target 
age group and 83.0% in the non-target age group, P = 0.011) were enrolled in the study. 
Their characteristics are listed in Table 1. Among the enrollees, 186 students (56.0%) 
were in the target age group, 168 of whom (90.3%) had already received the MR-IV 
vaccination. The number of students in the non-target age group was 146 (44.0%). 
Information on vaccination history is summarized in Table 2. A history of at least one 
measles vaccination was slightly more frequent among students in the target age group 
than in the non-target age group (98.9% vs. 95.4%, P = 0.07). A history of two or more 
measles vaccinations was significantly more frequent among students in the target age 
group than in the non-target age group (85.2% vs. 20.8%, P < 0.001). A history of at 
least one rubella vaccination in the target age group was significantly more frequent 
than in the non-target age group (98.9% vs. 77.5%, P < 0.001). A history of two or more 
rubella vaccinations in the target age group was significantly more frequent than in the 
non-target age group (54.9% vs. 13.2%, P < 0.001). 
Anti-measles immune status 
Anti-measles immune status is summarized in Table 2. The proportion of students with 
a history of measles infection was not significantly different between the target and non-
target age groups (8.8% vs. 6.3%, P = 0.41). Measles antibody titers were significantly 
higher among the target age group than the non-target age group (geometric mean titer, 
28.3 [–1 SD, 13.2; +1 SD, 60.6] vs. 16.8 [–1 SD, 6.9; +1 SD, 40.8]; P < 0.001). The 
prevalence of seropositivity against measles was also significantly higher among the 
target age group than the non-target age group (98.9% vs. 91.0%, P = 0.001). 
Anti-rubella immune status 
Anti-rubella immune status is summarized in Table 2. The proportion of students with a 
history of rubella infection was not significantly different between the two groups 
(11.0% vs. 9.9%, P = 0.75). Rubella antibody titers were significantly higher among the 
target age group than the non-target age group (geometric mean titer, 44.5 [–1 SD, 17.2; 
+1 SD, 115.0] vs. 30.8 [–1 SD, 9.7; +1 SD, 97.8]; P = 0.002). The prevalence of 
seropositivity against rubella was therefore significantly higher among the students in 






The students at the target MR-IV age had higher vaccine coverage and were more 
frequently seropositive against measles and rubella than those 1 year older than them. 
Even though a history of two or more vaccinations for measles and rubella remained 
85.2% and 54.9%, respectively, in the target age group, seropositivity against measles 
and rubella was 98.9% and 97.8%, respectively, achieving the WHO-recommended 
level for disease elimination at 95% and 85%.3–5 The prevalence of seropositivity 
against measles increased by 7.9% after this catch-up campaign. This is similar to the 
increase in measles immunity in the target age groups observed in previous catch-up 
campaigns in England and Wales, the Americas, Australia, and Korea.22,25–27 The 
Ministry of Health, Labor and Welfare of Japan also set a desired vaccination coverage 
of 95% for the two doses to eliminate measles by 2012. The MR-IV coverage of 90.3% 
in the present study and that of 77.3% in the nationwide survey, however, indicate that 
this level has not yet been reached.28 Further efforts to increase vaccine coverage should 
be made by local governments, by, for instance, periodic monitoring of vaccine 
coverage and repeated invitations to vaccinate those who are unvaccinated, along with 
close cooperation with schools and the board of education of local governments. 
The proportion of students with a history of at least one measles or rubella vaccination 
before the MR-IV period was higher in the non-target age group compared to the target 
age group. A considerable number of the 2008 first-year students might have received a 
MR vaccine in 2007 on their own, following the initiative according to the social 
requirements do so after the measles outbreak in 2006 and 2007, or in order to stay 
healthy for their entrance examinations. 
In the non-target age group, the seroprevalence for measles did not reach the WHO-
recommended level, and the two-dose measles and rubella vaccine coverage was far 
from the level demanded by the Japanese government. Thus, we still have a problem 
with insufficient immunization of youth who are not covered by the MR catch-up 
campaign. In particular, with regard to the future of health-care professionals, we need 
to provide an opportunity for further vaccination before clinical training. 
In light of the fact that more than half of the Japanese population receives higher 
education, university health services are expected to play a key role in preventing 
outbreaks of adolescent infectious diseases.29 Their easy access, during their routine 
activities, to the immune status of students from their history of infection and 
vaccination, would be the first step. One study showed that a questionnaire alone merely 
provides unreliable information regarding student immune status.30 In contrast, the 
MCH Handbook can provide more objective and precise information on infection and 
immune history and, therefore, should be utilized more. 
Some potential limitations of the current analysis must be acknowledged. First, only the 
specific anti-viral IgG antibody was measured for immune status. Immunoprophylaxis 
from infectious diseases involves the humoral, cellular and mucosal immune systems, 
and the anti-viral IgG antibody plays only a small role in humoral immunity. Anti-
measles- and anti-rubella-specific antibodies, however, have corresponded well with 
clinical response to infection.22,27,31–35 Furthermore, because measurement of the 
specific anti-viral IgG antibody is a relatively simple and economical method for 
ascertaining immune status compared to other laboratory examinations, the present 
results are easily applicable to clinical and public health settings. 
Second, there are some uncertainties about the external validity of the study results due 
to potential selection bias. Further studies are warranted to investigate whether the 
present findings are applicable to other Japanese universities. 
Third, the participation rate of the 2008 first-year students was significantly lower than 
that of the 2009 first-year students, which might distort the results. Because the included 
students were more selective and might have been more health-conscious in 2008 than 
in 2009, the better immune status of the target age students may have been 
underestimated. 





students who entered in 2008, which could have caused misclassification of 
immunization status. Consequently, the vaccine coverage of co-medical students in the 
non-target age group could be underestimated. 
From analyzing the data on the specific anti-viral IgG antibody titers and the 
vaccination and infection history among the 2008 and 2009 first-year university 
students, we conclude that the MR catch-up campaign helped achieve herd immunity 
and will contribute to the elimination of measles. 
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Male 137 (41.3) 332 82 (44.1) 186 55 (37.7) 146 0.24 




(18.7–18.8) 146 <0.001 
Available information        
 Antiviral antibody titers 327 (98.5) 332 183 (98.4) 186 144 (98.6) 146 1.00 
 Questionnaire 319 (96.1) 332 181 (97.3) 186 138 (94.5) 146 0.26 
 Photocopy of MCH Handbook 242 (72.9) 332 179 (96.2) 186 63 (43.2) 146 <0.001 
Actual vaccination in the MR-IV period – – 168 (90.3) 186 – – – 
MCH, maternal and child health; MR-IV, phase 4 measles/rubella-combined vaccination at age 17–18 years. 
 
 
Table 2 Immune status 
 
Target MR-IV age 
n (%) 




History of measles infection 16 (8.8) 182 8 (6.3) 127 0.41 
History of at least one measles vaccination before MR-IV period 160 (87.9) 182 124 (95.4) 130 0.02 
History of two or more measles vaccinations before MR-IV period 10 (5.5) 182 27 (20.8) 130 <0.001 
History of at least one measles vaccination including MR-IV period 180 (98.9) 182 124 (95.4) 130 0.07 
History of two or more measles vaccinations including MR-IV period 155 (85.2) 182 27 (20.8) 130 <0.001 
Antibody titer for measles (IU/mL) 28.3 (13.2, 60.6)† 183 16.8 (6.9, 40.8)† 144 <0.001‡ 
Immunopositivity against measles 181 (98.9) 183 131 (91.0) 144 0.001 
History of rubella infection 20 (11.0) 181 12 (9.9) 121 0.75 
History of at least one rubella vaccination before MR-IV period 107 (58.8) 182 100 (77.5) 129 0.001 
History of two or more rubella vaccinations before MR-IV period 9 (4.9) 182 17 (13.2) 129 0.01 
History of at least one rubella vaccination including MR-IV period 180 (98.9) 182 100 (77.5) 129 <0.001 
History of two or more rubella vaccinations including MR-IV period 100 (54.9) 182 17 (13.2) 129 <0.001 
Antibody titer for rubella (IU/mL) 44.5 (17.2, 115.0)† 183 30.8 (9.7, 97.8)† 144 0.002‡ 
Immunopositivity against rubella 179 (97.8) 183 120 (87.5) 144 <0.001 
†Geometric mean titer (–1 SD, +1 SD); ‡tested after logarithmic transformation. MR-IV, phase 4 measles/rubella-combined 
vaccination at age 17–18 years. 
 
